Christine Parseghian

12PUBLICATIONS
85CO-AUTHORS
ChemotherapyMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Applied statisticsPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (12)

|Aug 24, 2026
EMB-01, an Anti-EGFR/c-MET Bispecific Antibody, in Patients with Heavily Pretreated Metastatic Colorectal Cancer From a Phase Ib/II, Open-Label, Multicenter Study.

|Jan 13, 2026
Beyond the Burden: Elevating Immunotherapy in Colorectal Cancer.

Christine M Parseghian, Madhulika Eluri

|Jul 16, 2025
Phase II Trial of TAS-102 in Colorectal Cancer Patients With Circulating Tumor DNA-Defined Minimal Residual Disease After Adjuvant Therapy: INTERCEPT-TT.

Andrew J Pellatt, Alisha Bent, Nicholas Hornstein

|Aug 05, 2024
Secondary Endpoint Utilization and Publication Rate among Phase III Oncology Trials.

Esther J Beck, Alexander D Sherry, Marcus A Florez

|Dec 12, 2023
Sustained Disease Control in Immune Checkpoint Blockade Responders with Microsatellite Instability-high Colorectal Cancer after Treatment Termination.

Kristen Simmons, Jane V Thomas, Kaysia Ludford

|Oct 12, 2023
Novel Clinical Tool to Estimate Risk of False-Negative KRAS Mutations in Circulating Tumor DNA Testing.

Stefania Napolitano, Aparna R Parikh, Jason Henry

Pageof 2

Frequent Collaborators

7 joint publications

Scott Kopetz

6 joint publications

Michael Overman

6 joint publications

Van Morris

5 joint publications

Kanwal Raghav